Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma

p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo

(2017) Evguenia M Alexandrova et al.   Cell Death & Disease

Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus Carcinoma Oncogenes

(2015) Yiai Tong et al.   CANCER CELL

Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma

(2015) Giselle L. Saulnier Sholler et al.   Cancer Medicine

Targeting Oncogenic Mutant p53 for Cancer Therapy

(2015) Alejandro Parrales et al.   Frontiers in Oncology

Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

(2014) Susann Weissmueller et al.   CELL

Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups

(2014) D. M. Merino et al.   CLINICAL CANCER RESEARCH

Choroid plexus carcinomas are characterized by complex chromosomal alterations related to patient age and prognosis

(2014) Vincent Ruland et al.   GENES CHROMOSOMES & CANCER

Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience

(2014) Pavel Bezecny   MEDICAL ONCOLOGY

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma

(2014) Mikaela Porkholm et al.   PEDIATRIC BLOOD & CANCER

Current management of choroid plexus carcinomas

(2013) Matthew Z. Sun et al.   NEUROSURGICAL REVIEW

Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene

(2013) D Martin et al.   ONCOGENE

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

(2013) Jiri Polivka et al.   PHARMACOLOGY & THERAPEUTICS

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

(2012) H. Yang et al.   CLINICAL CANCER RESEARCH

Treatment of choroid plexus tumors: a 20-year single institutional experience

(2012) Chetan Bettegowda et al.   Journal of Neurosurgery-Pediatrics

Choroid plexus tumors in pediatric patients

(2011) Hideki Ogiwara et al.   BRITISH JOURNAL OF NEUROSURGERY

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

(2011) D Li et al.   CELL DEATH AND DIFFERENTIATION

Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors

(2011) Andreas Peyrl et al.   PEDIATRIC BLOOD & CANCER

Increased Incidence of Choroid Plexus Carcinoma Due to the Germline TP53 R337H Mutation in Southern Brazil

(2011) Gislaine Custodio et al.   PLoS One

Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage

(2010) Chiara Conti et al.   CANCER RESEARCH

TP53 Alterations Determine Clinical Subgroups and Survival of Patients With Choroid Plexus Tumors

(2010) Uri Tabori et al.   JOURNAL OF CLINICAL ONCOLOGY

Which therapy works better in choroid plexus carcinomas?

(2010) Su G. Berrak et al.   JOURNAL OF NEURO-ONCOLOGY

IDH mutations in glioma and acute myeloid leukemia

(2010) Lenny Dang et al.   TRENDS IN MOLECULAR MEDICINE

Platelet-Derived Growth Factor Receptor Expression and Activation in Choroid Plexus Tumors

(2009) Björn Koos et al.   AMERICAN JOURNAL OF PATHOLOGY

Dissecting the role of mTOR: Lessons from mTOR inhibitors

(2009) Ryan J.O. Dowling et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

2009 Version of the Chompret Criteria for Li Fraumeni Syndrome

(2009) Julie Tinat et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE